Dusseldorf - Delayed Quote EUR

Mithra Pharmaceuticals SA (1TM.DU)

0.2280

-0.0055

(-2.36%)

As of 8:11 AM GMT+2. Market Open.

Mithra reports full year 2023 financial results

Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from partnerships.Product sales were EUR 18.7 million, up +19.3% vs EUR 15.7 million in 2022.ESTELLE® product sales reached EUR 10.4 million in 2023 beating the September 2023 guidance of EUR 8.5 million and up from EUR 9.2 million in 2022.Cash position, at EUR 9.0 million at end of 2023, is down compared

GlobeNewswire last month

MITPF
Mithra announces changes to its executive management

Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the termination of the management agreement with David Horn Solomon1 as CEO and his replacement by Christophe Maréchal2 and Xavier Paoli as co-CEOs. As announced today, Mithra will commence a monetization process involving the sale of various selected assets of Mithra and/or the business as a whole (the "Monetiz

GlobeNewswire last month

MITPF
Mithra initiates monetization process, receives bridge loan from existing lenders

Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra has entered into a new secured bridge loan facility in a committed amount of up to EUR 13.5 million, subject to milestones; with an uncommitted facility of a further EUR 5 millionBridge loan facility provides expected liquidity runway to fund the monetization process with respect to key assets through 30

GlobeNewswire last month

MITPF
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat vasomotor symptoms (VMS) in menopauseMithra begins patient recruitment for the three proof-of-concept studies to explore treatment of symptoms beyond VMS Liege, Belgium, 28 February 2024 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces an achievement in its clinical re

GlobeNewswire last month

MITPF
Mithra sells shares in Mayne Pharma

Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra, the cash proceeds will be held in escrow by appointed security agents of lenders Liege, Belgium, 15 February 2024 – 08:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the sale of all 4,221,815 shares it held in Mayne Pharma Group Limited (ASX: MYX). The shares

GlobeNewswire 2 months ago

MITPF
Mithra updates on cash position

Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with stakeholdersMithra will present its results for the full year 2023 on 8 March 2024 Liege, Belgium, 6 February 2024 – 07:00 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today provides an update on its current cash position and its plans to address its runway and creating and optimizing value for

GlobeNewswire 2 months ago

MITPF
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the signing of the final license and supply agreementMithra is eligible to receive a total of EUR 2.05 million sales-related milestones, along with tiered double-digit royalties on annual net sales and payments at signature of the license agreement and for regulatory milestonesDONESTA® to target an addressable menopause

GlobeNewswire 3 months ago

MITPF
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric population could lead to six-month extension of the Supplementary Protection Certificate (SPC)1 and hence extended patent exclusivityStudy recruited more than 100 adolescents, with primary aim to evaluate safety profileLast subject, last visit now completed, with data expected in Q2 2024 Liege, Belgium, 20 D

GlobeNewswire 3 months ago

MITPF
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program has previously reported positive top-line data; extension to Europe trial ongoingAdditional endometrial data analyses ongoing for inclusion in regulatory submissionsMithra plans to submit DONESTA® for approval by U.S. and European regulators in Q4 2024 Liege, Belgium, 18 December 2023 – 7:00 CET – Mith

GlobeNewswire 3 months ago

MITPF
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter for the development and commercialization of ESTELLE ® and DONESTA® in ChinaMithra to receive EUR 4.5 million in combined milestone payments at signature of the license agreements with additional combined regulatory milestones of EUR 1.2 millionMithra eligible to receive a combined total of EUR 8.5 million sales

GlobeNewswire 4 months ago

MITPF
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to target the entire accessible US market of nearly 63 million women between the ages of 45 and 65, pending FDA approvalFollowing FDA advice, preparation of filing is proceeding with a filing date now planned in Q4 2024FDA marketing authorization, contingent upon successful completion of the approval process, now

GlobeNewswire 4 months ago

MITPF
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam Five abstracts on the positive effect of E4 accepted for oral presentationEleven leading experts to outline why estrogen is critical in contraception and for the treatment of postmenopausal symptomsData show promising efficacy and safety features of E4, key ingredient in ESTELLE® and DONESTA® Liege, Belgium, 28 November 2023 – 17:45 CET – Mithra (Euronext Brusse

GlobeNewswire 4 months ago

MITPF
Mithra’s NEXTSTELLIS® granted additional patent in the United States

Mithra’s NEXTSTELLIS® granted additional patent in the United States New patent extends protection for NEXTSTELLIS® (ESTELLE®) until 2036Mayne Pharma has a 20-year exclusive license and supply agreement in the US and Australia for NEXTSTELLIS® Liege, Belgium, 07 November 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that it has been granted an additional patent for NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in

GlobeNewswire 5 months ago

MITPF
Mithra releases invitation to its extraordinary securities holders’ meeting

Mithra releases invitation to its extraordinary securities holders’ meeting Liege, Belgium, 06 November 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has published and issued an invitation to its announced1 and conditionally planned for extraordinary securities holders’ meeting that will be held on Thursday, 23 November 2023, at 2:00 PM (CET). The notice for the extraordinary general meeting (EGM), including a description of t

GlobeNewswire 5 months ago

MITPF
Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada

Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada Mithra to receive EUR 1.5 million milestone payout as a result of the signing of the agreementAdditional licensing payout of EUR 15.55 million in regulatory and sales milestones, along with tiered royalties on annual net salesSearchlight anticipates filing of Canadian regulatory submission for DONESTA® as a treatment for the symptoms of menopause in H1 2024Both companies aim to provide innovative solutions to women by par

GlobeNewswire 5 months ago

MITPF
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong progress in 2016 agreement and further boosts Mithra’s cash positionAdditional EUR 10 million in milestone payments expected at approval of marketing authorizationMithra eligible for revenue from supply of the manufactured product post-commercialization Liege, Belgium, 23 October 2023 – 07:00 CEST – Mithra (Euro

GlobeNewswire 5 months ago

MITPF
Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting

Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting Liege, Belgium, 17 October 2023 – 7:00 CEST – Mithra (Euronext Brussels: MITRA) (the “Company”), a company dedicated to Women’s Health, announces today that following recommendation from its Nomination and Remuneration Committee, its Board of Directors has unanimously agreed by board resolution of yesterday to request the removal of the second agenda point entitl

GlobeNewswire 5 months ago

MITPF
Shareholder Letter

Dear Shareholders, We write to you today with a deep sense of responsibility and transparency, driven by our commitment to the principles of sound corporate governance and the long-term success of Mithra. We believe it is our duty to address recent developments concerning the request of some shareholders for the upcoming Special General Meeting of Shareholders ("SGM") to be held on October 30, 2023. The SGM will be followed by an Extraordinary Meeting of Shareholders ("EGM"). The main topics of

GlobeNewswire 6 months ago

MITPF
Mithra announces update to the agenda of its upcoming special general shareholders’ meeting

Liege, Belgium, 11 October 2023 – 7:00 CEST – Mithra (Euronext Brussels: MITRA) (the "Company"), a company dedicated to Women’s Health, today announces that it has received a request, in accordance with article 7:130 of the Belgian Companies and Associations Code, from a group of shareholders holding together more than 3% of the Company's outstanding shares to add additional items and resolutions to the agenda of its special general shareholders’ meeting ("SGM") that will be held on Monday, Octo

GlobeNewswire 6 months ago

MITPF
Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World Congress

Mithra to hold joint symposium with partner Gedeon Richter on 11 OctoberFour leading experts will outline why estrogens are critical in contraception and postmenopausal symptomsData show promising safety and efficacy features of E4, key ingredient in ESTELLE® and DONESTA® Liege, Belgium, 10 October 2023 – 18:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, will hold four presentations on the role of estrogens - including its Estetrol (E4) - in a symposium at th

GlobeNewswire 6 months ago

MITPF

Performance Overview

Return	1TM.DU	BEL 20
YTD	-81.55%	+3.08%
1-Year	-92.40%	-0.25%
3-Year	--	+2.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mithra Pharmaceuticals SA (1TM.DU)

Mithra reports full year 2023 financial results

Mithra announces changes to its executive management

Mithra initiates monetization process, receives bridge loan from existing lenders

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

Mithra sells shares in Mayne Pharma

Mithra updates on cash position

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Mithra releases invitation to its extraordinary securities holders’ meeting

Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting

Shareholder Letter

Mithra announces update to the agenda of its upcoming special general shareholders’ meeting

Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World Congress

Performance Overview